Boehringer Ingelheim has expanded its collaboration with Variant Bio into cardiovascular disease, adding an agreement that the companies said is potentially worth more than $250 million. The extension comes after Boehringer's January deal with the genomics-focused biotech, a $120 million biobucks pact aimed at using Variant's AI-powered Inference platform to discover and validate targets for cardiorenal and kidney disease.
Under the expanded agreement, Variant will receive an additional upfront payment and will be eligible for potential license and milestone payments totaling more than $250 million. The companies did not provide a more detailed breakdown.
Why Boehringer Expanded The Scope
Variant said the new collaboration will combine its platform and data-driven discovery capabilities with Boehringer's expertise in cardiovascular and kidney disease to identify potential new treatments for cardiovascular disease. In the company's description, the Inference platform integrates genomic, deep phenotyping and multiomic data from studies spanning global populations.
Søren Tullin, Boehringer's global head of cardiovascular-renal-metabolic diseases research, said the work will aim to identify genetically supported targets that could open paths to first-in-class treatments for people living with cardiovascular disease.
The strategic point is not simply that Boehringer is adding another disease area. Cardiovascular and kidney disease are closely interconnected, as Variant noted, so the expansion suggests Boehringer sees enough signal in the original discovery approach to widen the relationship rather than keep it confined to kidney-focused work.
The Broader Discovery Trend
Boehringer already has an established cardiovascular presence through products including Jardiance, Pradaxa and Twynsta, and it has also been studying vicadrostat with Jardiance in phase 3 trials in heart failure and chronic kidney disease. Bringing Variant deeper into that franchise shows where AI-enabled discovery is being asked to contribute: earlier target selection in disease areas with large commercial stakes and high development costs.
The timing also adds context. The expanded Variant deal arrived a day after Boehringer signed a separate $1 billion biobucks multiyear agreement with Envisagenics to validate tumor-specific targets. Other pharmas have made similar bets on Variant's approach as well, with Novo Nordisk entering a multiyear research pact in January 2025 to better understand the genetics underlying metabolic diseases across diverse populations.
The signal here is that AI in drug discovery is continuing to attract spend where it can improve target confidence, especially in broad chronic-disease markets where a better starting hypothesis can shape the economics of an entire pipeline.
